Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BICALUTAMIDE

8 general benefit · 1 not a benefit

Other products in the same Health Canada class (L02B, L02BB) — coverage varies; not interchangeable

  • Flutamide (Euflex): general benefit, Not a benefit
  • Enzalutamide (Xtandi): not a benefit
  • Abiraterone (Zytiga): general benefit
  • Anastrozole (Arimidex): general benefit
  • Degarelix (Firmagon): general benefit
  • Exemestane (Aromasin): general benefit

3 more in the class list below

Bicalutamide · DIN 02519178 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Bicalutamide · DIN 02519178 Manufacturer: Sanis Health Inc.; listing date 2022-06-30 Health Canada: Marketed since 2022-04-28 · brand BICALUTAMIDE · ATC L02BB03 BICALUTAMIDE · form Tablet · route Oral · ingredients BICALUTAMIDE 50 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Bicalutamide: Formulary list price $1.2690/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2690 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100844 · Verify on the e-Formulary ↗ (DIN 02519178)

Source record
DIN 02519178: Bicalutamide Raw flags: sec3=Y Item: 100000108; group id 145; item number 0244; lccId None; manufacturer id SAI Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2690; ministry $1.2690 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519178 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100844
Interchangeable products
Apo-Bicalutamide · DIN 02296063 · $1.2690 Bicalutamide Tablets · DIN 02325985 · $1.2690 Casodex · DIN 02184478 · not recorded Co Bicalutamide · DIN 02274337 · $1.2690 Jamp-Bicalutamide · DIN 02357216 · $1.2690 PMS-Bicalutamide · DIN 02275589 · $1.2690 Ran-Bicalutamide · DIN 02371324 · $1.2690 Teva-Bicalutamide · DIN 02270226 · $1.2690
Shortage status: resolved shortage (ended 2025-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519178
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bicalutamide Tablets · DIN 02325985 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Bicalutamide Tablets · DIN 02325985 Manufacturer: Accord Healthcare Inc.; listing date 2010-07-20 Health Canada: Marketed since 2014-08-23 · brand ACH-BICALUTAMIDE · ATC L02BB03 BICALUTAMIDE · form Tablet · route Oral · ingredients BICALUTAMIDE 50 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Bicalutamide Tablets: Formulary list price $1.2690/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2690 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81133 · Verify on the e-Formulary ↗ (DIN 02325985)

Source record
DIN 02325985: Bicalutamide Tablets Raw flags: sec3=Y Item: 100000108; group id 145; item number 0244; lccId None; manufacturer id ACH Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2690; ministry $1.2690 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02325985 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81133
Interchangeable products
Apo-Bicalutamide · DIN 02296063 · $1.2690 Bicalutamide · DIN 02519178 · $1.2690 Casodex · DIN 02184478 · not recorded Co Bicalutamide · DIN 02274337 · $1.2690 Jamp-Bicalutamide · DIN 02357216 · $1.2690 PMS-Bicalutamide · DIN 02275589 · $1.2690 Ran-Bicalutamide · DIN 02371324 · $1.2690 Teva-Bicalutamide · DIN 02270226 · $1.2690
Shortage status: resolved shortage (ended 2026-02-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02325985
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Bicalutamide · DIN 02357216 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Bicalutamide · DIN 02357216 Manufacturer: Jamp Pharma Corporation; listing date 2011-03-15 Health Canada: Marketed since 2026-05-21 · brand JAMP BICALUTAMIDE · ATC L02BB03 BICALUTAMIDE · form Tablet · route Oral · ingredients BICALUTAMIDE 50 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Bicalutamide: Formulary list price $1.2690/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2690 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84234 · Verify on the e-Formulary ↗ (DIN 02357216)

Source record
DIN 02357216: Jamp-Bicalutamide Raw flags: sec3=Y Item: 100000108; group id 145; item number 0244; lccId None; manufacturer id JPC Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2690; ministry $1.2690 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357216 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84234
Interchangeable products
Apo-Bicalutamide · DIN 02296063 · $1.2690 Bicalutamide · DIN 02519178 · $1.2690 Bicalutamide Tablets · DIN 02325985 · $1.2690 Casodex · DIN 02184478 · not recorded Co Bicalutamide · DIN 02274337 · $1.2690 PMS-Bicalutamide · DIN 02275589 · $1.2690 Ran-Bicalutamide · DIN 02371324 · $1.2690 Teva-Bicalutamide · DIN 02270226 · $1.2690
Shortage status: resolved shortage (ended 2022-10-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02357216
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Bicalutamide · DIN 02275589 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Bicalutamide · DIN 02275589 Manufacturer: Pharmascience Inc.; listing date 2006-04-04 Health Canada: Marketed since 2006-02-08 · brand PMS-BICALUTAMIDE · ATC L02BB03 BICALUTAMIDE · form Tablet · route Oral · ingredients BICALUTAMIDE 50 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Bicalutamide: Formulary list price $1.2690/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2690 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76122 · Verify on the e-Formulary ↗ (DIN 02275589)

Source record
DIN 02275589: PMS-Bicalutamide Raw flags: sec3=Y Item: 100000108; group id 145; item number 0244; lccId None; manufacturer id PMS Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2690; ministry $1.2690 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02275589 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76122
Interchangeable products
Apo-Bicalutamide · DIN 02296063 · $1.2690 Bicalutamide · DIN 02519178 · $1.2690 Bicalutamide Tablets · DIN 02325985 · $1.2690 Casodex · DIN 02184478 · not recorded Co Bicalutamide · DIN 02274337 · $1.2690 Jamp-Bicalutamide · DIN 02357216 · $1.2690 Ran-Bicalutamide · DIN 02371324 · $1.2690 Teva-Bicalutamide · DIN 02270226 · $1.2690
Shortage status: resolved shortage (ended 2023-06-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02275589
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Bicalutamide · DIN 02270226 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Bicalutamide · DIN 02270226 Manufacturer: Teva Canada Limited; listing date 2006-04-04 Health Canada: Marketed since 2015-05-06 · brand TEVA-BICALUTAMIDE · ATC L02BB03 BICALUTAMIDE · form Tablet · route Oral · ingredients BICALUTAMIDE 50 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Bicalutamide: Formulary list price $1.2690/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2690 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75561 · Verify on the e-Formulary ↗ (DIN 02270226)

Source record
DIN 02270226: Teva-Bicalutamide Raw flags: sec3=Y Item: 100000108; group id 145; item number 0244; lccId None; manufacturer id TEV Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2690; ministry $1.2690 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02270226 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75561
Interchangeable products
Apo-Bicalutamide · DIN 02296063 · $1.2690 Bicalutamide · DIN 02519178 · $1.2690 Bicalutamide Tablets · DIN 02325985 · $1.2690 Casodex · DIN 02184478 · not recorded Co Bicalutamide · DIN 02274337 · $1.2690 Jamp-Bicalutamide · DIN 02357216 · $1.2690 PMS-Bicalutamide · DIN 02275589 · $1.2690 Ran-Bicalutamide · DIN 02371324 · $1.2690
Shortage status: resolved shortage (ended 2024-02-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02270226
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Bicalutamide · DIN 02296063 · 50mg · tablet

General benefitDormant since 2023-05-14 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Bicalutamide · DIN 02296063 Manufacturer: Apotex Inc.; listing date 2008-01-15 Health Canada: Dormant since 2023-05-14 · brand APO-BICALUTAMIDE · ATC L02BB03 BICALUTAMIDE · form Tablet · route Oral · ingredients BICALUTAMIDE 50 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Bicalutamide: Formulary list price $1.2690/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2690 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78142 · Verify on the e-Formulary ↗ (DIN 02296063)

Source record
DIN 02296063: Apo-Bicalutamide Raw flags: sec3=Y Item: 100000108; group id 145; item number 0244; lccId None; manufacturer id APX Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2690; ministry $1.2690 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02296063 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78142
Interchangeable products
Bicalutamide · DIN 02519178 · $1.2690 Bicalutamide Tablets · DIN 02325985 · $1.2690 Casodex · DIN 02184478 · not recorded Co Bicalutamide · DIN 02274337 · $1.2690 Jamp-Bicalutamide · DIN 02357216 · $1.2690 PMS-Bicalutamide · DIN 02275589 · $1.2690 Ran-Bicalutamide · DIN 02371324 · $1.2690 Teva-Bicalutamide · DIN 02270226 · $1.2690
Shortage status: discontinued (2022-05-12, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02296063
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2023-05-14 — choose a marketed DIN from the same-category list.

Co Bicalutamide · DIN 02274337 · 50mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2018-07-11 — choose a marketed DIN from the same-category list.Discontinued 2018-07-11 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-07-11 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-07-11 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Co Bicalutamide · DIN 02274337 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2006-04-04 Health Canada: Cancelled post market since 2018-07-11 · brand ACT BICALUTAMIDE · ATC L02BB03 BICALUTAMIDE · form Tablet · route Oral · ingredients BICALUTAMIDE 50 MG · company Actavis pharma company · schedule Prescription
Check this DIN again · Health Canada product record

Co Bicalutamide: Formulary list price $1.2690/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2690 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75978 · Verify on the e-Formulary ↗ (DIN 02274337)

Source record
DIN 02274337: Co Bicalutamide Raw flags: sec3=Y Item: 100000108; group id 145; item number 0244; lccId None; manufacturer id COB Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2690; ministry $1.2690 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02274337 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75978
Interchangeable products
Apo-Bicalutamide · DIN 02296063 · $1.2690 Bicalutamide · DIN 02519178 · $1.2690 Bicalutamide Tablets · DIN 02325985 · $1.2690 Casodex · DIN 02184478 · not recorded Jamp-Bicalutamide · DIN 02357216 · $1.2690 PMS-Bicalutamide · DIN 02275589 · $1.2690 Ran-Bicalutamide · DIN 02371324 · $1.2690 Teva-Bicalutamide · DIN 02270226 · $1.2690
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02274337
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-07-11 — choose a marketed DIN from the same-category list.

Ran-Bicalutamide · DIN 02371324 · 50mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-08-23 — choose a marketed DIN from the same-category list.Discontinued 2022-08-23 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-08-23 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-08-23 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Bicalutamide · DIN 02371324 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2011-12-15 Health Canada: Cancelled post market since 2022-08-23 · brand RAN-BICALUTAMIDE · ATC L02BB03 BICALUTAMIDE · form Tablet · route Oral · ingredients BICALUTAMIDE 50 MG · company Ranbaxy pharmaceuticals canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Bicalutamide: Formulary list price $1.2690/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2690 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85649 · Verify on the e-Formulary ↗ (DIN 02371324)

Source record
DIN 02371324: Ran-Bicalutamide Raw flags: sec3=Y Item: 100000108; group id 145; item number 0244; lccId None; manufacturer id RAN Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2690; ministry $1.2690 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02371324 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85649
Interchangeable products
Apo-Bicalutamide · DIN 02296063 · $1.2690 Bicalutamide · DIN 02519178 · $1.2690 Bicalutamide Tablets · DIN 02325985 · $1.2690 Casodex · DIN 02184478 · not recorded Co Bicalutamide · DIN 02274337 · $1.2690 Jamp-Bicalutamide · DIN 02357216 · $1.2690 PMS-Bicalutamide · DIN 02275589 · $1.2690 Teva-Bicalutamide · DIN 02270226 · $1.2690
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02371324
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-08-23 — choose a marketed DIN from the same-category list.

Casodex · DIN 02184478 · 50mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-03-07 — choose a marketed DIN from the same-category list.Discontinued 2025-03-07 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-03-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-03-07 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Casodex (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists CASODEX (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)
1 brand, same coverage
Casodex · DIN 02184478 Manufacturer: AstraZeneca; listing date 1996-12-19 Health Canada: Cancelled post market since 2025-03-07 · brand CASODEX · ATC L02BB03 BICALUTAMIDE · form Tablet · route Oral · ingredients BICALUTAMIDE 50 MG · company Astrazeneca canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Casodex: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19647 · Verify on the e-Formulary ↗ (DIN 02184478)

Source record
DIN 02184478: Casodex Raw flags: notABenefit=Y, sec3=Y Item: 100000108; group id 145; item number 0244; lccId None; manufacturer id AZC Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02184478 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19647
Interchangeable products
Apo-Bicalutamide · DIN 02296063 · $1.2690 Bicalutamide · DIN 02519178 · $1.2690 Bicalutamide Tablets · DIN 02325985 · $1.2690 Co Bicalutamide · DIN 02274337 · $1.2690 Jamp-Bicalutamide · DIN 02357216 · $1.2690 PMS-Bicalutamide · DIN 02275589 · $1.2690 Ran-Bicalutamide · DIN 02371324 · $1.2690 Teva-Bicalutamide · DIN 02270226 · $1.2690
Shortage status: discontinued (2025-02-06, reported by ASTRAZENECA CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02184478
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-03-07 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

FLUTAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

ENZALUTAMIDE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

LETROZOLE

· 20 products · General benefit · strengths: 2.5mg · Tab

TAMOXIFEN CITRATE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 10mg, 20mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-BICALUTAMIDE (bicalutamide) 50 mg is indicated for use in combination therapy with either a luteinizing hormone releasing hormone (LHRH) analogue or surgical castration in the treatment of metastatic (Stage D2) prostate cancer. Pediatrics: The safety and effectiveness of bicalutamide in children has not been established. https://pdf.hres.ca/dpd_pm/00041652.PDF PM date: September 27, 2017 Source product: TEVA-BICALUTAMIDE; DIN 02270226; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Bicalutamide · DIN 02296063 Shortage status: discontinued (2022-05-12, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02296063

Check this DIN again

Casodex · DIN 02184478 Shortage status: discontinued (2025-02-06, reported by ASTRAZENECA CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02184478

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Casodex: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026